S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:ISEE

IVERIC bio (ISEE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$39.95
$39.95
50-Day Range
$36.90
$39.95
52-Week Range
$9.39
$39.99
Volume
N/A
Average Volume
3.62 million shs
Market Capitalization
$5.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

ISEE stock logo

About IVERIC bio Stock (NASDAQ:ISEE)

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.


ISEE Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Apellis adds safety warning to eye therapy
Astellas Completes Acquisition of Iveric Bio
B.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)
Iveric bio, Still A 5+% Opportunity
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
IVERIC Bio (NASDAQ: ISEE)
Check Out What Whales Are Doing With ISEE
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2023
Today
2/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$35.00
Low Stock Price Target
$29.00
Potential Upside/Downside
-19.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-185,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.43 per share

Miscellaneous

Free Float
134,063,000
Market Cap
$5.50 billion
Optionable
Optionable
Beta
1.06
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives















ISEE Stock Analysis - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price target for 2024?

8 brokerages have issued twelve-month price targets for IVERIC bio's stock. Their ISEE share price targets range from $29.00 to $35.00. On average, they predict the company's share price to reach $32.00 in the next twelve months. This suggests that the stock has a possible downside of 19.9%.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) posted its earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.10. During the same period in the previous year, the firm earned ($0.29) EPS.

What ETFs hold IVERIC bio's stock?

ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), AltShares Event-Driven ETF (EVNT) and Vanguard Russell 2000 Growth ETF (VTWG).Vanguard Russell 2000 ETF (VTWO).

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

This page (NASDAQ:ISEE) was last updated on 2/25/2024 by MarketBeat.com Staff